UK markets closed
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • FTSE 250

    22,984.24
    +123.85 (+0.54%)
     
  • AIM

    1,229.10
    +4.02 (+0.33%)
     
  • GBP/EUR

    1.1848
    +0.0063 (+0.53%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • BTC-GBP

    44,983.13
    +2,814.23 (+6.67%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • DOW

    35,294.76
    +382.20 (+1.09%)
     
  • CRUDE OIL

    82.66
    +1.35 (+1.66%)
     
  • GOLD FUTURES

    1,768.10
    -29.80 (-1.66%)
     
  • NIKKEI 225

    29,068.63
    +517.70 (+1.81%)
     
  • HANG SENG

    25,330.96
    +368.37 (+1.48%)
     
  • DAX

    15,587.36
    +124.64 (+0.81%)
     
  • CAC 40

    6,727.52
    +42.31 (+0.63%)
     

Global Human Growth Hormone Drugs Market to Reach $4 Billion by 2026

·26-min read

Abstract: Global Human Growth Hormone Drugs Market to Reach $4 Billion by 2026 The human growth hormone, which is also known as somatropin, is a peptide hormone that is secreted by pituitary gland, which regulates cell regeneration, cell growth, metabolism, and reproduction.

New York, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Human Growth Hormone Drugs Industry" - https://www.reportlinker.com/p05443628/?utm_source=GNW
The level of growth hormones should be optimum in human body for normal growth. It can be regulated by several factors such as sleep, stress, exercise, and lower levels of glucose. Human growth hormones help to control body composition, bone and muscle growth, sugar and fat metabolism, recovery from injuries, and body fluids. They also help in boosting muscle strength and performance. Improper levels of growth hormones may affect the quality of life, intensifying the risks of health disorders such as high levels of cholesterol, decreased bone density, and deficiency in growth hormones. While lower levels of the growth hormones result in fat accumulation in the human body, higher levels result in gigantism in children and short bowel syndrome and muscle-wasting disease in adults. With growing age, the human growth hormone levels decrease. This natural process of slowing down of the growth hormone production in human body has raised the interest in synthetic hormone therapies globally.

Amid the COVID-19 crisis, the global market for Human Growth Hormone Drugs estimated at US$3.3 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2026, growing at a CAGR of 3.5% over the analysis period. Subcutaneous, one of the segments analyzed in the report, is projected to grow at a 4% CAGR to reach US$2.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Intramuscular segment is readjusted to a revised 3.1% CAGR for the next 7-year period. This segment currently accounts for a 23.7% share of the global Human Growth Hormone Drugs market.

The U.S. Market is Estimated at $1.3 Billion in 2021, While China is Forecast to Reach $285.1 Million by 2026

The Human Growth Hormone Drugs market in the U.S. is estimated at US$1.3 Billion in the year 2021. The country currently accounts for a 40.12% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$285.1 Million in the year 2026 trailing a CAGR of 5.2% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3% CAGR while Rest of European market (as defined in the study) will reach US$299.1 Million by the close of the analysis period.

The market is expected to witness growth owing to surge in cases related to pituitary dysfunction, and increasing number of health disorders in children, mainly owing to changes in food habits. Some other major factors that have been driving the market growth are advancement of recombinant HGH drugs, and increasing off-label use of human growth hormones. Also, increase in awareness with regards to treatment processes; increasing aging population; increasing neuropsychiatric cases; increasing funds by governments for research and development within the endocrinology sector; introduction of technological advancements within the healthcare sector for enhancing quality of services; increasing rate of consumption of the drugs in key applications. Additionally, initiatives adopted by private and public organizations for promoting healthcare-related policies and services in the under-developing and developed companies is also boosting market for human growth hormones globally. Also, demand from people for effective treatment processes and rise in disposable income among the urban population is likely to offer market growth opportunities. Increasing prevalence of adopting latest technologies in regards to pill production at low cost is also likely to positively impact market demand for human growth hormones. Increased FDA approvals are offering immense opportunities to companies for developing new, more effective drugs, with lesser side effects. The market will also benefit from increasing number of health disorders in children, mainly owing to changes in food habits. Also, increase in awareness in regards to treatment processes; increasing aging population; increasing neuropsychiatric cases; increasing funds by governments for research and development within the endocrinology sector; introduction of technological advancements within the healthcare sector for enhancing quality of services; increasing rate of consumption of the drugs in key applications; increasing approvals by FDA along with other government organizations; as well as increase in research organizations pertaining to the biotechnology field is driving market growth. Additionally, initiatives adopted by private and public organizations for promoting healthcare-related policies and services in the under-developing and developed companies is also boosting market for human growth hormones globally.

Intravenous Segment to Reach $304.8 Million by 2026

In the global Intravenous segment, USA, Canada, Japan, China and Europe will drive the 2.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$231.8 Million in the year 2020 will reach a projected size of US$269.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$14.4 Million by the year 2026.
Select Competitors (Total 46 Featured)

  • AnkeBio Co. Ltd

  • Eli Lilly and Company

  • EMD Serono Inc.

  • Ferring Pharmaceuticals

  • Genentech, Inc (Roche)

  • GeneScience Pharmaceuticals Co. Ltd

  • Ipsen S.A.

  • LG Life Sciences

  • Merck KGaA

  • Novo Nordisk A/S

  • Pfizer, Inc

  • Sandoz International GmbH (Novartis AG)

  • Strongbridge Biopharma

  • Teva Pharmaceutical Industries, Ltd




Read the full report: https://www.reportlinker.com/p05443628/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
A Prelude to Human Growth Hormones
Recombinant Human Growth Hormones
Evolution of Recombinant Human Growth Hormones (hGH)
COVID-19 Impact on Human Growth Hormone Drugs
GLOBAL MARKET OVERVIEW
Global Human Growth Hormone Drugs Market to Witness Steady Growth
List of Select Approved Prescription Daily-dose hGH Products by
Indication
List of Select Approved Prescription Weekly-dose hGH Products
by Indication
Subcutaneous Route Dominates Human Growth Hormone Drugs Market
Growth Hormone Deficiency Application Leads the Human Growth
Hormone Drugs Market
North America and Europe Dominate, Asia-Pacific to Witness
Fastest Growth
Market Restraints
Competition
EXHIBIT 1: Leading Global Recombinant hGH Products Market:
(2020): Annual Sales in US$ Million for Norditropin,
Genotropin, Humatrope, Nutropin, Saizen, EGRIFTA
EXHIBIT 2: Global Recombinant hGH Products Market (2020):
Market Share of Leading Players
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
High Prevalence of Growth Hormone Deficiency Disorders
Pediatric GHD Rules, while Adult GHD Remains Underserved
EXHIBIT 3: Worldwide Recombinant Human Growth Hormone Market by
Indication (2020): Percentage Breakdown of Value Sales for
Pediatric GHD; Adult GHD, Turner Syndrome & Idiopathic Short
Stature; and Others
Long-Acting hGH Drugs - A Game Changer for the Human Growth
Hormone Drugs Market
Approval of Novo Nordisk?s Once-Weekly Sogroya to Transform the
Market Landscape
Other Noteworthy Developments in the Long Acting hGH Space
Patent Expiry Paves Way for the Emergence of Biosimilars
Strong Innovation Drive Takes Hold of the hGH Industry
Manufacturers Bet on Novel Drug Delivery Technologies
Non-Prescription/Off-Label Usage - A Concern
Needle-less Drug Delivery Systems to Wipe Out of Syringes
Drug Delivery Device Options for Marketed hGH Products
Major Growth Restraining Factors
Complex Delivery System
High Cost of hGH Treatment
Biosimilars Threaten Revenue Growth Erosion
PIPELINE ANALYSIS
Select Daily and Long-Acting Human Growth Hormone Products List
in Phase III Pipeline

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Human Growth
Hormone Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Human Growth Hormone Drugs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Human Growth Hormone
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2021 & 2027

Table 4: World Current & Future Analysis for Subcutaneous by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Subcutaneous by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Subcutaneous by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 7: World Current & Future Analysis for Intramuscular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Intramuscular by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Intramuscular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Current & Future Analysis for Intravenous by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Intravenous by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Intravenous by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 13: World Current & Future Analysis for Oral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 16: World Current & Future Analysis for Hospital Pharmacy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Hospital Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Hospital Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Current & Future Analysis for Specialty
Pharmacy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Specialty Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Specialty Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Current & Future Analysis for Retail Pharmacy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Retail Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Retail Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 25: World Current & Future Analysis for Online Pharmacy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Online Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Online Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 28: World Current & Future Analysis for Growth Hormone
Deficiency by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Growth Hormone Deficiency
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Growth Hormone
Deficiency by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

Table 31: World Current & Future Analysis for Turner Syndrome
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 32: World Historic Review for Turner Syndrome by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Turner Syndrome by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 34: World Current & Future Analysis for Idiopathic Short
Stature (ISS) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Idiopathic Short Stature
(ISS) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Idiopathic Short
Stature (ISS) by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2021 & 2027

Table 37: World Current & Future Analysis for Prader-Willi
Syndrome (PWS) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Prader-Willi Syndrome (PWS)
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Prader-Willi Syndrome
(PWS) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027

Table 40: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 41: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 42: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 43: USA Current & Future Analysis for Human Growth
Hormone Drugs by Route Of Administration - Subcutaneous,
Intramuscular, Intravenous and Oral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 44: USA Historic Review for Human Growth Hormone Drugs by
Route Of Administration - Subcutaneous, Intramuscular,
Intravenous and Oral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Human Growth Hormone
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Subcutaneous, Intramuscular, Intravenous and
Oral for the Years 2012, 2021 & 2027

Table 46: USA Current & Future Analysis for Human Growth
Hormone Drugs by Distribution Channel - Hospital Pharmacy,
Specialty Pharmacy, Retail Pharmacy and Online Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for Human Growth Hormone Drugs by
Distribution Channel - Hospital Pharmacy, Specialty Pharmacy,
Retail Pharmacy and Online Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 48: USA 15-Year Perspective for Human Growth Hormone
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacy, Specialty Pharmacy, Retail
Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

Table 49: USA Current & Future Analysis for Human Growth
Hormone Drugs by Application - Growth Hormone Deficiency,
Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi
Syndrome (PWS) and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: USA Historic Review for Human Growth Hormone Drugs by
Application - Growth Hormone Deficiency, Turner Syndrome,
Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: USA 15-Year Perspective for Human Growth Hormone
Drugs by Application - Percentage Breakdown of Value Sales for
Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short
Stature (ISS), Prader-Willi Syndrome (PWS) and Other
Applications for the Years 2012, 2021 & 2027

CANADA
Table 52: Canada Current & Future Analysis for Human Growth
Hormone Drugs by Route Of Administration - Subcutaneous,
Intramuscular, Intravenous and Oral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 53: Canada Historic Review for Human Growth Hormone Drugs
by Route Of Administration - Subcutaneous, Intramuscular,
Intravenous and Oral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Human Growth Hormone
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Subcutaneous, Intramuscular, Intravenous and
Oral for the Years 2012, 2021 & 2027

Table 55: Canada Current & Future Analysis for Human Growth
Hormone Drugs by Distribution Channel - Hospital Pharmacy,
Specialty Pharmacy, Retail Pharmacy and Online Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for Human Growth Hormone Drugs
by Distribution Channel - Hospital Pharmacy, Specialty
Pharmacy, Retail Pharmacy and Online Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 57: Canada 15-Year Perspective for Human Growth Hormone
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacy, Specialty Pharmacy, Retail
Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

Table 58: Canada Current & Future Analysis for Human Growth
Hormone Drugs by Application - Growth Hormone Deficiency,
Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi
Syndrome (PWS) and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 59: Canada Historic Review for Human Growth Hormone Drugs
by Application - Growth Hormone Deficiency, Turner Syndrome,
Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Canada 15-Year Perspective for Human Growth Hormone
Drugs by Application - Percentage Breakdown of Value Sales for
Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short
Stature (ISS), Prader-Willi Syndrome (PWS) and Other
Applications for the Years 2012, 2021 & 2027

JAPAN
Table 61: Japan Current & Future Analysis for Human Growth
Hormone Drugs by Route Of Administration - Subcutaneous,
Intramuscular, Intravenous and Oral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 62: Japan Historic Review for Human Growth Hormone Drugs
by Route Of Administration - Subcutaneous, Intramuscular,
Intravenous and Oral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Human Growth Hormone
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Subcutaneous, Intramuscular, Intravenous and
Oral for the Years 2012, 2021 & 2027

Table 64: Japan Current & Future Analysis for Human Growth
Hormone Drugs by Distribution Channel - Hospital Pharmacy,
Specialty Pharmacy, Retail Pharmacy and Online Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for Human Growth Hormone Drugs
by Distribution Channel - Hospital Pharmacy, Specialty
Pharmacy, Retail Pharmacy and Online Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 66: Japan 15-Year Perspective for Human Growth Hormone
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacy, Specialty Pharmacy, Retail
Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

Table 67: Japan Current & Future Analysis for Human Growth
Hormone Drugs by Application - Growth Hormone Deficiency,
Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi
Syndrome (PWS) and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: Japan Historic Review for Human Growth Hormone Drugs
by Application - Growth Hormone Deficiency, Turner Syndrome,
Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Japan 15-Year Perspective for Human Growth Hormone
Drugs by Application - Percentage Breakdown of Value Sales for
Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short
Stature (ISS), Prader-Willi Syndrome (PWS) and Other
Applications for the Years 2012, 2021 & 2027

CHINA
Table 70: China Current & Future Analysis for Human Growth
Hormone Drugs by Route Of Administration - Subcutaneous,
Intramuscular, Intravenous and Oral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 71: China Historic Review for Human Growth Hormone Drugs
by Route Of Administration - Subcutaneous, Intramuscular,
Intravenous and Oral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Human Growth Hormone
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Subcutaneous, Intramuscular, Intravenous and
Oral for the Years 2012, 2021 & 2027

Table 73: China Current & Future Analysis for Human Growth
Hormone Drugs by Distribution Channel - Hospital Pharmacy,
Specialty Pharmacy, Retail Pharmacy and Online Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for Human Growth Hormone Drugs
by Distribution Channel - Hospital Pharmacy, Specialty
Pharmacy, Retail Pharmacy and Online Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 75: China 15-Year Perspective for Human Growth Hormone
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacy, Specialty Pharmacy, Retail
Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

Table 76: China Current & Future Analysis for Human Growth
Hormone Drugs by Application - Growth Hormone Deficiency,
Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi
Syndrome (PWS) and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 77: China Historic Review for Human Growth Hormone Drugs
by Application - Growth Hormone Deficiency, Turner Syndrome,
Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: China 15-Year Perspective for Human Growth Hormone
Drugs by Application - Percentage Breakdown of Value Sales for
Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short
Stature (ISS), Prader-Willi Syndrome (PWS) and Other
Applications for the Years 2012, 2021 & 2027

EUROPE
Table 79: Europe Current & Future Analysis for Human Growth
Hormone Drugs by Geographic Region - France, Germany, Italy,
UK, Spain, Russia and Rest of Europe Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 80: Europe Historic Review for Human Growth Hormone Drugs
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 81: Europe 15-Year Perspective for Human Growth Hormone
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2021 & 2027

Table 82: Europe Current & Future Analysis for Human Growth
Hormone Drugs by Route Of Administration - Subcutaneous,
Intramuscular, Intravenous and Oral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 83: Europe Historic Review for Human Growth Hormone Drugs
by Route Of Administration - Subcutaneous, Intramuscular,
Intravenous and Oral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Human Growth Hormone
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Subcutaneous, Intramuscular, Intravenous and
Oral for the Years 2012, 2021 & 2027

Table 85: Europe Current & Future Analysis for Human Growth
Hormone Drugs by Distribution Channel - Hospital Pharmacy,
Specialty Pharmacy, Retail Pharmacy and Online Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for Human Growth Hormone Drugs
by Distribution Channel - Hospital Pharmacy, Specialty
Pharmacy, Retail Pharmacy and Online Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 87: Europe 15-Year Perspective for Human Growth Hormone
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacy, Specialty Pharmacy, Retail
Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

Table 88: Europe Current & Future Analysis for Human Growth
Hormone Drugs by Application - Growth Hormone Deficiency,
Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi
Syndrome (PWS) and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 89: Europe Historic Review for Human Growth Hormone Drugs
by Application - Growth Hormone Deficiency, Turner Syndrome,
Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 90: Europe 15-Year Perspective for Human Growth Hormone
Drugs by Application - Percentage Breakdown of Value Sales for
Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short
Stature (ISS), Prader-Willi Syndrome (PWS) and Other
Applications for the Years 2012, 2021 & 2027

FRANCE
Table 91: France Current & Future Analysis for Human Growth
Hormone Drugs by Route Of Administration - Subcutaneous,
Intramuscular, Intravenous and Oral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 92: France Historic Review for Human Growth Hormone Drugs
by Route Of Administration - Subcutaneous, Intramuscular,
Intravenous and Oral Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 93: France 15-Year Perspective for Human Growth Hormone
Drugs by Route Of Administration - Percentage Breakdown of
Value Sales for Subcutaneous, Intramuscular, Intravenous and
Oral for the Years 2012, 2021 & 2027

Table 94: France Current & Future Analysis for Human Growth
Hormone Drugs by Distribution Channel - Hospital Pharmacy,
Specialty Pharmacy, Retail Pharmacy and Online Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 95: France Historic Review for Human Growth Hormone Drugs
by Distribution Channel - Hospital Pharmacy, Specialty
Pharmacy, Retail Pharmacy and Online Pharmacy Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 96: France 15-Year Perspective for Human Growth Hormone
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacy, Specialty Pharmacy, Retail
Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

Table 97: France Current & Future Analysis for Human Growth
Hormone Drugs by Application - Growth Hormone Deficiency,
Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi
Syndrome (PWS) and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 98: France Historic Review for Human Growth Hormone Drugs
by Application - Growth Hormone Deficiency, Turner Syndrome,
Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS) and
Other Applications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 99: France 15-Year Perspective for Human Growth Hormone
Drugs by Application - Percentage Breakdown of Value Sales for
Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short
Stature (ISS), Prader-Willi Syndrome (PWS) and Other
Applications for the Years 2012, 2021 & 2027

GERMANY
Table 100: Germany Current & Future Analysis for Human Growth
Hormone Drugs by Route Of Administration - Subcutaneous,
Intramuscular, Intravenous and Oral - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 101: Germany Historic Review for Human Growth Hormone

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05443628/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting